How Long Until Immunotherapy Pays Off in Lung Cancer? New Study Puts a Number on It
A reconstructed analysis of ten randomized trials finds that perioperative immunotherapy for resectable lung cancer delivers a 10% reduction in ...
A reconstructed analysis of ten randomized trials finds that perioperative immunotherapy for resectable lung cancer delivers a 10% reduction in ...
A sweeping 2024–2025 evidence review shows immune checkpoint inhibitors, frailty-adapted surgery, and artificial intelligence converging to transform esophageal cancer treatment ...
Final Phase 3 IMpower030 results show that perioperative atezolizumab plus chemotherapy extended median event-free survival to 62.8 months versus 34.9 ...
Success! An email was just sent to confirm your subscription. Please find the email now and click 'Confirm Follow' to start subscribing.
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine